Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications

ConditionsPost-COVID-19 Condition Ulcerative Colitis Crohn Disease Calciphylaxis Frostbite Acute COVID-19 Pyoderma Gangrenosum Pterygium Hypospadias Head Trauma Pneumatosis Intestinalis Ischemic Bowel Raynaud Syndrome Malignant Otitis Externa Nonarteritic Anterior Ischemic Optic Neuropathy Central Retinal Vein Occlusion Femoral Head Necrosis Invasive Fungal Infection Chronic Anal Fissure Vasculitic Ulcer Graft-vs-Host Disease Decubitus Ulcer Greater Trochanteric Pain Syndrome Rectovaginal Fistula Pouchitis Tinnitus Clostridium Enterocolitis Branch Retinal Artery Occlusion Axonotmesis Multiple Sclerosis Inclusion Body Myositis Epidermolysis Bullosa (EB)Osteonecrosis Ulcer Ischemic Avascular Necrosis of Bone Prosthesis Related Infections Facial Filler Injections Cystitis Chronic Ligament Injury Anastomosis, Leaking Cartilage Injury

Trial statusNot yet recruiting

Trial phasePhase 4

Trial typeInterventional

Biological sexAll

AgeNot listed

SponsorJay C. Buckey Jr.

About this trial

This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric Oxygen Treatment. The study team aims to collect ongoing data on how well HBOT treats these emerging indications, and to add these data to the growing HBO Registry. The research team hypothesizes that HBOT will result in improvements of the condition of the various emerging indications.

Eligibility criteria

Qualifiers

Patients referred for HBOT with an emerging indication

Disqualifiers

Contraindication to hyperbaric oxygen treatment (untreated seizures, pneumothorax, significant pulmonary airspace pathology that might lead to pulmonary barotrauma, unmanageable confinement anxiety, chronic obstructive pulmonary disease with CO2 retention)

Pregnant persons

Trial design

Treatments tested in this trial

Hyperbaric oxygen treatment (HBOT)
100% Oxygen

Treatment groups

100 Participants

are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators

Jay C. Buckey Jr.

Lead sponsor

Dartmouth-Hitchcock Medical Center

Sponsor institution

Dartmouth College

Collaborator

Source ClinicalTrials.gov